[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-368889-105":59,"doc-detail-368889-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","upfront-surgery-versus-induction-chemotherapy-followed-by-surgery-in-oral-cavity-squamous-cell-cancers-with-advanced-nodal-disease-survic-trial-a-phase-3-multicentre-randomised-controlled-trial","Upfront surgery versus induction chemotherapy followed by surgery in oral cavity squamous cell cancers with advanced nodal disease (SurVIC Trial) - a phase 3 multicentre randomised controlled trial","","Most oral cancers in India present at advanced stages and often lead to poor oncological outcomes. Although chemotherapy can improve outcomes in other cancers, its curative role in oral squamous cell cancer is not well defined, and prior neoadjuvant trials showed limited benefit. This phase 3 open-label multicentre trial evaluates whether adding induction chemotherapy before surgery improves two-year disease-free survival in operable oral cavity squamous cell carcinoma with advanced nodal disease (N2–N3), alongside overall survival, response, toxicity, quality of life, compliance, and postoperative complications.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/upfront-surgery-versus-induction-chemotherapy-followed-by-surgery-in-oral-cavity-squamous-cell-cancers-with-advanced-nodal-disease-survic-trial-a-phase-3-multicentre-randomised-controlled-trial/368889/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/upfront-surgery-versus-induction-chemotherapy-followed-by-surgery-in-oral-cavity-squamous-cell-cancers-with-advanced-nodal-disease-survic-trial-a-phase-3-multicentre-randomised-controlled-trial/368889.png","ImageObject",300,407,{"name":92,"@type":93},"Bulrr","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-28","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What question does the SurVIC Trial address?","Question",{"text":112,"@type":113},"The trial aims to determine the oncological advantage of adding induction chemotherapy before surgery in operable oral squamous cell cancer with advanced nodal disease (N2–N3).","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How is the study designed and what are the treatment arms?",{"text":117,"@type":113},"It is an open-label, multicentre, randomised controlled trial with a 1:1 allocation. Patients receive either surgery first (SURG) with adjuvant radiotherapy, or two cycles of induction chemotherapy (cisplatin-based regimens) followed by surgery and adjuvant radiotherapy.",{"name":119,"@type":110,"acceptedAnswer":120},"What are the primary and key secondary outcomes?",{"text":121,"@type":113},"The primary objective compares two-year disease-free survival (DFS) with and without induction chemotherapy before surgery. Secondary objectives include overall survival, response rates, compliance, treatment completion, adverse events, toxicity (CTCAE v5.0), quality of life, and postoperative complications (modified Clavien-Dindo).","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},368889,1790810673,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},5909892115043,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Open access Protocol  \n Upfront surgery versus induction  \nchemotherapy followed by surgery in oral cavity squamous cell cancers with advanced nodal disease (SurVIC Trial): a phase 3 multicentre randomised controlled trial  \nDharma Ram Poonia  ,1 Amit Sehrawat,2 Jeewan Ram Vishnoi,1  \nNivedita Sharma,3 Parmod Kumar,4 Bharti Devnani,3 Aparna Warriere,5 Akanksha Solanki,3 Puneet Pareek,3 Divya Aggarwal,3 Taruna Yadav,3 Prem Prakash Sharma,6 Ashita Gadwal,1 Anushka Goyal,3 Poonam Elhence,7 Pushpinder Khera,3 Ashish Jakhetiya,8 Pnahindra Swaim,9 Dillip Muduly,9 Rohit Mahajan,10 Pankaj Garg,11 Vijay Kumar,12 Madhabananda Kar,13 Sanjeev Misra14  \nTo cite: Poonia DR, Sehrawat A, Vishnoi JR, et al. Upfront surgery versus induction chemotherapy followed by surgery in oral cavity squamous cell cancers with advanced nodal disease (SurVIC Trial): a phase 3 multicentre randomised controlled trial. BMJ Open 2025;15:e106644 . doi:10 . 1136/ bmjopen-2025-106644  \n► Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online ([https://doi.org/10.1136/](https://doi.org/10.1136/)[ ](https://doi.org/10.1136/)[bmjopen-2025-106644](bmjopen-2025-106644)) .  \nReceived 16 June 2025  \nAccepted 11 September 2025  \n© Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.  \nFor numbered affiliations see end of article.  \nCorrespondence to  \nDr Dharma Ram Poonia; [drdharmapoonia@gmail.com](drdharmapoonia@gmail.com)  \nABSTRACT  \nIntroduction Most oral cancers in India present in advanced stages and tend to have poor oncological outcomes. Chemotherapy has been associated with improved oncological outcomes in various cancers, but its role in oral cancer is still not well-defined in curative settings beyond radiosensitisation. Despite an excellent response rate, neoadjuvant chemotherapy trials have failed to show an oncological advantage. Earlier studies were limited by their heterogeneous patient population, including all head and neck subsites, and included both inoperable cancer and early-stage operable cases. Due to such patient selection, the intended results were never met. Patients with biologically aggressive diseases (advanced nodal disease) may derive greater benefit from induction chemotherapy (ICT) . Therefore, we aim to determine the oncological advantage of adding ICT to oral squamous cell cancer with advanced nodal disease (N2–N3) .  \nMethods and analysis The study is an open-label, multicentre, randomised controlled trial, with an allocation ratio of 1:1, being conducted at seven leading cancer centres in India. The primary objective is to compare survival outcomes with and without ICT before surgery inpatients with oral squamous cell carcinoma (OSCC) and advanced nodal disease, specifically focusing on 2-year disease-free survival (DFS) . Secondary objectives include assessing overall survival (OS), clinical and pathological response rates, treatment compliance, treatment completion rates, adverse events, treatment-related toxicity (using Common Terminology Criteria for Adverse Events, V.5.0), quality of life (measured with Functional Assessment of Cancer Therapy-General and Functional  \nAssessment of Cancer Therapy-Head and Neck) and postoperative complications (using the modified ClavienDindo classification) .  \nSTRENGTHS AND LIMITATIONS OF THIS STUDY   \n⇒ Focused population: restricted to operable oral cavity squamous cell carcinoma with advanced nodal disease (N2–N3), ensuring relevance, but this narrow scope may limit generalisability beyond similar high-risk Indian patients.  \n⇒ Multicentre, randomised design: inclusion of seven cancer centres with standardised eligibility criteria enhances external validity, though the Indiaonly setting may constrain applicability to global populations.  \n⇒ Comprehensive endpoints: capture disease-free survival, overall survi","cbCaii1UwjtPwhIJ","https://ap.wps.com/l/cbCaii1UwjtPwhIJ","pdf",334735,"English","# Abstract\n## Introduction\n## Methods and analysis\n## Strengths and limitations\n## Study population and interventions","[{\"question\":\"What question does the SurVIC Trial address?\",\"answer\":\"The trial aims to determine the oncological advantage of adding induction chemotherapy before surgery in operable oral squamous cell cancer with advanced nodal disease (N2–N3).\"},{\"question\":\"How is the study designed and what are the treatment arms?\",\"answer\":\"It is an open-label, multicentre, randomised controlled trial with a 1:1 allocation. Patients receive either surgery first (SURG) with adjuvant radiotherapy, or two cycles of induction chemotherapy (cisplatin-based regimens) followed by surgery and adjuvant radiotherapy.\"},{\"question\":\"What are the primary and key secondary outcomes?\",\"answer\":\"The primary objective compares two-year disease-free survival (DFS) with and without induction chemotherapy before surgery. Secondary objectives include overall survival, response rates, compliance, treatment completion, adverse events, toxicity (CTCAE v5.0), quality of life, and postoperative complications (modified Clavien-Dindo).\"}]","Upfront surgery versus induction chemotherapy followed by surgery in oral cavity squamous cell cancers with advanced nodal disease (SurVIC Trial) - a phase 3 multicentre randomised controlled trial | PDF",1790179100,23,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f92458b82eed015aab371a75c33f405b.webp",983,1310,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5c727d7a871a55b3e27dadf21da16db1.webp",982,1309,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cf310a14f542bb6052aa58ebcfa0ca1d.webp",981,1308,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ac3f317e74bb6e4fb7c5d4e2c006c6c6.webp",980,1306]